![NOVO NORDISK INC.: Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes | American Pharmacy News NOVO NORDISK INC.: Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes | American Pharmacy News](https://s3.amazonaws.com/jnswire/jns-media/31/83/762303/tusok.png)
NOVO NORDISK INC.: Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes | American Pharmacy News
![Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity | Fierce Pharma Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1641325621/NovoNordisk.jpg/NovoNordisk.jpg?VersionId=oXA1EdZFAwk38Tx6WNblYWz7nEC7E06P)
Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity | Fierce Pharma
![Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes - PharmTech Focus Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes - PharmTech Focus](http://pharmtechfocus.com/wp-content/uploads/2022/03/Novo-Nordisk-Receives-Fda-Approval-of-Higher-dose-Ozempic%C2%AE-2-Mg-Providing-Increased-Glycemic-Control-for-Adults-With-Type-2-Diabetes-1.jpg)
Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes - PharmTech Focus
![Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR](http://www.koreabiomed.com/news/photo/202204/13597_14138_1024.jpg)
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
![Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2021/02/shutterstock_1224254950-1.jpg)